A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced
non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm,
multicenter, phase II study